Avapritinib 4-Year PIONEER Data: Sustained QoL Gains in ISM

Four-year data from the PIONEER trial show that avapritinib continues to improve emotional well-being and social functioning in patients with indolent systemic mastocytosis (ISM), extending beyond symptom and biomarker control alone, according to Thanai Pongdee, MD, of Mayo Clinic.¹

The analysis, presented at the European Academy of Allergy & Clinical Immunology (EAACI) 2026 Annual Meeting in Istanbul, followed 226 patients who initiated avapritinib 25 mg once daily across parts 1, 2, and 3 of the trial. The median treatment duration was 46.5 months, ranging from 0.7 to 67.2 months.

Emotional and Social Functioning Gains With Avapritinib

Pongdee said the findings matter because chronic disease burden extends well beyond physical symptoms. Patients with ISM often withdraw from daily activities out of fear that a flare could occur without warning.

“We want patients to be able to function in their daily activities, whether it be work or social situations, because [the] disease, being chronic in nature, can significantly impact those kinds of activities and emotional well-being. Anything that can improve those aspects of a disease [is] as equally important as symptom control.”

Nearly half of patients reported less fear of an allergic reaction after long-term treatment, according to Pongdee. He said anaphylaxis-related anxiety is a major driver of quality-of-life impairment in ISM because reactions are frequently unpredictable.

"There's this constant worry that this could happen at any time," Pongdee said. He pointed to a previously published retrospective report suggesting avapritinib may reduce anaphylactic event risk, though he noted this remains under further investigation and was not a primary endpoint of PIONEER.

Sustained Quality of Life Improvement in ISM

Mean total symptom score on the ISM-Symptom Assessment Form (ISM-SAF TSS) and mean percentage change in Mastocytosis Quality of Life Questionnaire (MC-QoL) total score both showed continued improvement from baseline through 1 (-17.66 and -30.96, respectively) and 4 years (-17.66 and -35.41). These extended findings build on the placebo-controlled portion of PIONEER, in which avapritinib produced rapid, durable, and clinically meaningful improvements in ISM symptoms and quality of life compared with placebo through 24 weeks.²

By 1 year, 31% of patients (n = 69) had reduced or discontinued use of ≥ 1 class of best supportive care (BSC) medication; by 3 years, that proportion rose to 52% (n = 118). The largest reductions were seen with cromolyn sodium (36.5%), anti-immunoglobulin E therapy (34.5%), and H1 (31.2%) and H2 (28.8%) antihistamines.

4-Year PIONEER Safety Findings

The safety profile of avapritinib with a median treatment duration of approximately 4 years remained consistent with what was previously reported in the placebo-controlled portion of the trial. Discontinuations due to treatment-related adverse events remained limited, occurring in 3% of patients (n = 6); grade ≥ 3 treatment-related adverse events stayed low.

The most frequently reported treatment-related adverse events were edema events, most of which were grade 1. Rates of cognitive adverse events and increased transaminases remained low and similar to placebo from the earlier controlled portion of the study, and no intracranial bleeds were observed. 1 death occurred during the study but was deemed unrelated to treatment, attributed to anaphylaxis in the context of atrial fibrillation in a patient with a prior history of both conditions.

“Decreasing [the anaphylaxis] risk…frees people…to do activities that we would consider pretty typical [but] would have otherwise been avoided,” Pongdee concluded. “Someone who never went out to eat, never went to a school reunion, [never attended] an employee picnic—things that a lot of us take for granted—can also enjoy those same activities.”

Reported disclosures for Pongdee include GlaxoSmithKline and Blueprint Medicines Corporation.

Reference

1. Broesby-Olsen S, Siebenhaar F, Oude Elberink H, et al. Mastocytosis Treated With Avapritinib: Updated 4-Year Results From The PIONEER Trial. Presented at European Academy of Allergy & Clinical Immunology (EAACI) 2026 Annual Meeting from June 12-15, 2026 in Istanbul, Türkiye.

2. Akin C. Long-Term PIONEER Data Reinforce Avapritinib’s Benefit–Risk Profile in ISM, with Cem Akin, MD. HCPLive. March 3, 2026. Accessed July 13, 2026. https://www.hcplive.com/view/long-term-pioneer-data-reinforce-avapritinib-benefit-risk-profile-ism-akin-md